Lobbyists might have taken a collective breather after their megabill lobbying blitz, but the brief respite won’t last. President Donald Trump’s tariffs and trade deals are back center stage as Congress gears up for a slew of business that cuts across K Street sectors: appropriations, crypto legislation, a federal funding rescissions package, the annual defense policy measure, and more. President Donald Trump, joined by Republican lawmakers, signs the One, Big Beautiful Bill Act into law last Friday. Photographer: Samuel Corum/Getty Images Even if Congress is done with the one big bill now that it’s one big law, that doesn’t mean lobbyists are. - “We make money off the next phase,” said Rich Gold, who leads the public policy and regulation group at Holland & Knight.
Not only will K Street denizens work to influence federal regulators as they implement the law, but lobbyists also see litigation looming. Some provisions, given recent Supreme Court decisions that limited deference to federal agencies when Congress isn’t clear, may have “trouble surviving judicial review once implemented by an agency,” Gold said. Jane Lucas, a partner at Alston & Bird, said the “details of these forthcoming regulations are critical” to clients, even as lobbyists work Capitol Hill, too. - “The next big process to watch in the legislative branch is the appropriations process with the rescissions package creating a new dynamic for both sides to navigate as the fiscal year comes to a close,” said Lucas, a longtime aide to Senate Majority Leader John Thune (R-S.D.).
Big-dollar lobbying fights will also rage over pieces that didn’t make it in the megalaw, such as changes for pharmacy benefit managers. The Trump administration’s agenda, especially on trade and immigration, will consume K Street’s attention. Trump said his latest deadline of Aug. 1 for tariffs was firm. - “It’s going to be a lot busier than people expect,” said Republican lobbyist Ozzie Palomo, founding partner of Chartwell Strategy Group.
Also Read: Welcome to the latest edition of Power Play, Bloomberg Government’s newsletter on the lobbying, money, and people moving Capitol Hill’s agenda from the outside. Reach out with tips, news, complaints, and most importantly all your exclusives: kackley@bloombergindustry.com.
|
|
|
The Senate Banking Committee is holding a hearing on crypto. Photographer: Timothy Fadek/Bloomberg Looking for crypto lobbyists today? They’re swarming the Senate Banking panel, which plans a hearing on digital assets. Summer Mersinger, the new CEO of the Blockchain Association and a former aide to Thune, is set to appear. Ditto for Jonathan Levin, CEO of Chainalysis, and Ripple CEO Brad Garlinghouse, according to the committee. Ballard Partners, Michael Best Strategies, FGS Global, and the Conaway Graves Group – the firm of former Rep. Mike Conaway (R-Texas) – are registered to lobby for Ripple, disclosure filings show. Twenty-First Century Group lobbied for Chainalysis on issues “related to tracking of illicit financial activity on the blockchain; blockchain intelligence,” per a first-quarter filing.
- Republicans are planning a big focus on crypto legislation next week with House leaders designating it “Crypto Week” as part of an effort “to deliver on President Trump’s promise to make the United States the world leader in digital assets,” House Majority Leader Steve Scalise (R-La.) said in a statement.
|
|
|
Photo Illustration: David Evans/Bloomberg Law; Photo: Getty Images Squire Patton Boggs registered for the Palestine Monetary Authority in Washington for $500,000 a year starting July 1, according to new filings with the Justice Department’s Foreign Agents Registration Act unit. - The team at Squire Patton Boggs includes the firm’s global managing partner Ed Newberry; Gassan A. Baloul, who co-chairs the Middle East Practice; International Affairs Adviser Paul Jones; and David Schnittger, a longtime aide to former House Speaker John Boehner (R-Ohio).
Squire Patton Boggs, which also represents the Palestinian Authority, will provide “lobbying services” on Capitol Hill, including the congressional committees overseeing banking and foreign affairs policy, and at the US Treasury and State departments, the FARA filings say. The Palestine Monetary Authority is the central bank of Palestine, the filing noted. The firm also will offer “strategic guidance on issues relating to reputational and regulatory risk, and recommendations and guidance regarding the PMA’s in-person visits to Washington,” the contract said.
|
|
|
More change is ahead for Avoq, one of Washington’s largest lobbying practices. CEO Nicole Cornish plans to step down from the top role by year’s end, though remain on the board, the firm said Tuesday. Avoq has launched a search for her successor and is looking for someone to “lead Avoq into its next phase of evolution,” the firm said in a news release. Cornish was at the helm when the company forged a partnership with Coral Tree Partners, a private equity firm based in Los Angeles. Whit Askew, a former House GOP leadership aide, and Cedric Grant, a former chief of staff to House Democratic Leader Hakeem Jeffries, took the rein’s of Avoq’s government relations operation from managing partners Steve Elmendorf and Jimmy Ryan in May, as Power Play first reported. The firm also does communications work and has offices around the country including Chicago, New York, and Miami.
|
|
|
Monument Advocacy this week acquired the health policy firm Horizon Government Affairs, marking Monument’s first transaction since it announced investment last October from Everlane Equity Partners, a private equity firm. Horizon will take the Monument Advocacy moniker and its President and CEO Joel White will be a partner at Monument, the firm said. Horizon disclosed about $430,000 in federal lobbying revenue in the first quarter of this year. Monument’s clients include JPMorgan Chase, Amazon.com, and PepsiCo Inc., lobbying disclosures show. - The two shops have shared clients, including the drug industry’s lead lobby Pharmaceutical Research and Manufacturers of America, as recently as this year, federal lobbying disclosures show.
Everlane and Monument Advocacy said more deals were ahead.
|
|
|
In the States California lawmakers are keeping up the pressure on drug price middlemen after Congress dropped provisions tightening rules on the industry from President Donald Trump’s tax-and-spending bill. Read More
|
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era drug price negotiations that doubles down on actions they’ve resisted since the program began. Read More
|
|
|
|